NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
UMIN ID: C000000130

Registered date:12/09/2005

Phase II study of topotecan and amrubicin for metastatic or relapsed small-cell lung cancer

Basic Information

Recruitment status Complete: follow-up complete
Health condition(s) or Problem(s) studiedMetastatic or relapsed small-cell lung cancer
Date of first enrollment2004/04/01
Target sample size30
Countries of recruitmentJapan
Study typeInterventional
Intervention(s)Combination chemotherapy of topotecan and amrubicin

Outcome(s)

Primary OutcomeResponse rate
Secondary OutcomeAdverse events, overall survival, progression-free survival

Key inclusion & exclusion criteria

Age minimum20years-old
Age maximum75years-old
GenderMale and Female
Include criteria
Exclude criteriaActive concomitant malignancy Active interstitial pneumonia Massive effusions Unstable angina, recent myocardial infarction Uncontrolled diabetes Severe active infection Other severe complications Pregnant or lactating women Inappropriate condition for this study judged by physicians.

Related Information

Contact

public contact
Name Katsuyuki Hotta
Address 2-5-1 Shikata-cho, Okayama 700-8558 Japan
Telephone 086-235-7227
E-mail khotta@md.okayama-u.ac.jp
Affiliation Okayama Lung Cancer Study Group Coordinating Office Department of Respiratory Medicine, Okayama University Hospital
scientific contact
Name Mitsune Tanimoto
Address 2-5-1 Shikata-cho, Okayama 700-8558 Japan
Telephone 086-235-7227
E-mail
Affiliation Okayama University Hospital Hematology, Oncology, Respiratory Medicine